Discover and read the best of Twitter Threads about #revived
Most recents (4)
📌#Revisión & #Metaanálisis. Revascularización en Cardiopatía Isquémica c/FEY <35%: para quienes y como.
4⃣ECR & 2.4K👥
🔹HEART (#HF #Revascularisation Trial)
🔸STICH (Surgical Treatment for #Ischemic HF)
🔹PARR-2 (PET and Recovery Following Revascularization)
🔸REVIVED-BCIS2
4⃣ECR & 2.4K👥
🔹HEART (#HF #Revascularisation Trial)
🔸STICH (Surgical Treatment for #Ischemic HF)
🔹PARR-2 (PET and Recovery Following Revascularization)
🔸REVIVED-BCIS2
🔹HEART (6%👥) FEY 24%. CABG vs OMT. Viabilidad todos.
🔸STICH/STICHES (49%👥) FEY 28%. CABG vs OMT. Viabilidad discrecional🩺.
🔹PARR-2 (17%👥) FEY 27%. tto guiado x imágenes
🔸REVIVED (28%👥) FEY 27%. PCI vs OMT. 14% TCI y 58% DA prox. Viabilidad todos.
👇Para guardar
🔸STICH/STICHES (49%👥) FEY 28%. CABG vs OMT. Viabilidad discrecional🩺.
🔹PARR-2 (17%👥) FEY 27%. tto guiado x imágenes
🔸REVIVED (28%👥) FEY 27%. PCI vs OMT. 14% TCI y 58% DA prox. Viabilidad todos.
👇Para guardar
📌Rol de la isquemia:
🔸Basado en estudios históricos: MASS II.
🔹STICH (nuclear) no mostró beneficio y sí un pequeño subanálisis del ISCHEMIA (gráfico)
🔸Aún👉recomendación clase I p/👥c/ enf. multivaso + isquemia inducible y FEY severa, aunque la evidencia actual no lo avala⛔️
🔸Basado en estudios históricos: MASS II.
🔹STICH (nuclear) no mostró beneficio y sí un pequeño subanálisis del ISCHEMIA (gráfico)
🔸Aún👉recomendación clase I p/👥c/ enf. multivaso + isquemia inducible y FEY severa, aunque la evidencia actual no lo avala⛔️
Follow this #CardioTwitter #Thread
to get an overview of ALL
🚨#ESCcongress #HotLineSessions🚨
Including:
➡️14 #OnePager #CongressCards
➡️Links to on-demand stream
➡️Jorunal weblinks
➡️Hashtag of the author/presenter
PART 1 ⬇️
to get an overview of ALL
🚨#ESCcongress #HotLineSessions🚨
Including:
➡️14 #OnePager #CongressCards
➡️Links to on-demand stream
➡️Jorunal weblinks
➡️Hashtag of the author/presenter
PART 1 ⬇️
1.1./ #TIME trial - The Treatment in Morning versus Evening study.
📕🔗:: NOT YET PUBLISHED
On-demand ESC 📺: bit.ly/3AQuvkB
#ESCcongress
📕🔗:: NOT YET PUBLISHED
On-demand ESC 📺: bit.ly/3AQuvkB
#ESCcongress
#ESCCongress
A bit of a deep dive on #REVIVED - not ocean floor deep, but just a little more than below the surface!
A lot has already been discussed today, so I'll try not to be too repetitive
A bit of a deep dive on #REVIVED - not ocean floor deep, but just a little more than below the surface!
A lot has already been discussed today, so I'll try not to be too repetitive
#ESCCongress
This was NOT a trial of revasc in highly symptomatic patients or ACS patients. It was designed to answer the Q of whether PCI is beneficial in ischaemic myocardial dysfunction / ischaemic cardiomyopathy
This was NOT a trial of revasc in highly symptomatic patients or ACS patients. It was designed to answer the Q of whether PCI is beneficial in ischaemic myocardial dysfunction / ischaemic cardiomyopathy
#ESCCongress
These multi-centre RCTs are very hard work for steering committees and PIs, huge congrats to everyone that worked on delivering this trial - well done!
These multi-centre RCTs are very hard work for steering committees and PIs, huge congrats to everyone that worked on delivering this trial - well done!
MIC drop at #ESCCongress
No difference at all with revascularization in patients with ischemic cardiomyopathy.
There is silence in the audience! Woooowwwwww
@mmamas1973 @DrMarthaGulati @mirvatalasnag @iamritu @djc795 @SrihariNaiduMD @adityadoc1 @KemalogluOz @Hragy
No difference at all with revascularization in patients with ischemic cardiomyopathy.
There is silence in the audience! Woooowwwwww
@mmamas1973 @DrMarthaGulati @mirvatalasnag @iamritu @djc795 @SrihariNaiduMD @adityadoc1 @KemalogluOz @Hragy
#ESCCongress
Conclusions of #REVIVED trial —
In Patients with ICM — PCI didn’t reduce the all cause mortality or heart failure hospitalization at 3.4 years.
( including left main disease)
@DmitryAbramovMD @VinoyPrasadMD @adityadoc1 @datsunian @DineshKalra @DrSharathS
Conclusions of #REVIVED trial —
In Patients with ICM — PCI didn’t reduce the all cause mortality or heart failure hospitalization at 3.4 years.
( including left main disease)
@DmitryAbramovMD @VinoyPrasadMD @adityadoc1 @datsunian @DineshKalra @DrSharathS
Excellent discussion at #ESCCongress
REVIVED trial
💥 GDMT works — 90% on BB &ARNI/ACE/ ARB
💥 LVEF increase with PCI doesn’t help with CHF or MI, but better life quality
💥 does viability matter? For risk stratification
@VDelgadoGarcia @alexsfelixecho @Sarah_Moharem
REVIVED trial
💥 GDMT works — 90% on BB &ARNI/ACE/ ARB
💥 LVEF increase with PCI doesn’t help with CHF or MI, but better life quality
💥 does viability matter? For risk stratification
@VDelgadoGarcia @alexsfelixecho @Sarah_Moharem
